EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Mycophenolate mofetil for the treatment of acute and chronic steroid-refractory graft-versus-host disease



Mycophenolate mofetil for the treatment of acute and chronic steroid-refractory graft-versus-host disease



Annals of Hematology 84(10): 681-685



Corticosteroid-resistant graft-versus-host disease (GvHD) is difficult to manage and is associated with high morbidity and mortality. The purpose of our study was to evaluate the safety and efficacy of mycophenolate mofetil (MMF) as the salvage therapy for steroid-refractory GvHD. Twenty one patients (10 with acute GvHD and 11 with chronic GvHD) were studied retrospectively.

(PDF emailed within 0-6 h: $19.90)

Accession: 012337523

Download citation: RISBibTeXText

PMID: 16001244

DOI: 10.1007/s00277-005-1070-0



Related references

Mycophenolate mofetil as salvage treatment for steroid-refractory chronic graft versus-host disease in children. Blood 98(11 Part 1): 398a, November 16, 2001

Mycophenolate mofetil for treatment of steroid-refractory acute graft-versus-host disease after pediatric hematopoietic stem cell transplantation. Pediatric Transplantation 19(6): 652-658, 2016

Mycophenolate mofetil is effective and well tolerated in the treatment of refractory acute and chronic graft-versus-host disease. International Journal of Hematology 83(1): 80-85, 2006

Combination antithymocyte globulin and soluble TNF alpha inhibitor (etanercept) +/- mycophenolate mofetil for treatment of steroid refractory acute graft-versus-host disease. Bone Marrow Transplantation 37(12): 1143-1147, 2006

Mycophenolate mofetil is effective only for involved skin in the treatment for steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Annals of Hematology: -, 2016

Mycophenolate mofetil as rescue therapy for high-risk steroid-refractory chronic graft versus-host-disease. Pediatric Research 53(4 Part 2): 275A, April, 2003

Revisiting mycophenolate mofetil for steroid-refractory acute graft-versus-host disease: Is higher dosing effective in children?. Pediatric Transplantation 19(6): 582-583, 2016

The use mycophenolate mofetil in the treatment of refractory chronic graft versus host disease. Blood 92(10 SUPPL 1 PART 1-2): 346B, Nov 15, 1998

Treatment of acute and chronic graft versus host disease with mycophenolate mofetil. Blood 94(10 SUPPL 1 PART 2): 368b, Nov 15, 1999

Mycophenolate mofetil (MMF) for refractory chronic graft versus host disease (cGvHD). Haematologica 88(8): Elt28; Author Reply Elt29-Elt28; Author Reply Elt29, 2003

Salvage therapy with mycophenolate mofetil and FK-506 for refractory chronic graft-versus-host disease. Blood 92(10 SUPPL 1 PART 1-2): 457A, Nov 15, 1998

Response to mycophenolate mofetil therapy for refractory chronic graft-versus-host disease. Haematologica 88(7): 837-839, July, 2003

Salvage therapy for refractory chronic graft-versus-host disease with mycophenolate mofetil and tacrolimus. Bone Marrow Transplantation 24(5): 517-520, Sept 1, 1999

A high risk of life-threatening infectious complications in mycophenolate mofetil treatment for acute or chronic graft-versus-host disease. International Journal of Hematology 91(3): 464-470, 2010

Mycophenolate mofetil for the treatment of chronic graft versus host disease of the liver. Blood 94(10 SUPPL 1 PART 1): 159a, Nov 15, 1999